Characteristics of clinical study group (third phase study) and comparison with field study group (second phase study)
| Neuropathy classification | ||||
|---|---|---|---|---|
| Variable | None | Possible | Probable or definite | Field study group |
| Attending (n) | 17 | 38 | 24 | |
| Analysed (n) | 15 | 34 | 23 | 612 |
| Sex: | ||||
| Female | 2 | 5 | 3 | 88 |
| % | 13 | 15 | 13 | 14 |
| Age (y): | ||||
| Mean | 38.8 | 46.2 | 46.1 | 45.1 |
| SD | 13.3 | 10.6 | 11.0 | 13.4 |
| Range | 20–66 | 30–64 | 22–62 | 15–75 |
| Alcohol (units/week): | ||||
| Mean | 9.0 | 10.4 | 8.4 | 8.2 |
| SD | 6.7 | 8.5 | 9.8 | 10.2 |
| Range | 0–20 | 1–40 | 0–38 | 0–45 |
| Country: | ||||
| Scotland | 10 | 28 | 13 | 344 |
| % | 59 | 78 | 57 | 56 |
| Cumulative exposure (OPEXP): | ||||
| Mean | 1349 | 4364 | 1758 | 2400 |
| SD | 1638 | 8011 | 1486 | 4280 |
| Range | 10–6534 | 68–44010 | 12–6088 | 0–48810 |